Compare WERN & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WERN | ALVO |
|---|---|---|
| Founded | 1956 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1994 | 2021 |
| Metric | WERN | ALVO |
|---|---|---|
| Price | $27.60 | $4.29 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 7 |
| Target Price | ★ $36.67 | $7.50 |
| AVG Volume (30 Days) | ★ 984.6K | 904.9K |
| Earning Date | 10-27-2026 | 11-11-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $2,974,396,000.00 | N/A |
| Revenue This Year | $22.96 | $10.60 |
| Revenue Next Year | $8.31 | $22.47 |
| P/E Ratio | $201.75 | ★ $18.20 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.06 | $2.94 |
| 52 Week High | $47.49 | $6.53 |
| Indicator | WERN | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 38.18 | 39.19 |
| Support Level | $26.85 | $3.10 |
| Resistance Level | $29.68 | $4.59 |
| Average True Range (ATR) | 0.99 | 0.29 |
| MACD | 0.22 | -0.02 |
| Stochastic Oscillator | 25.00 | 16.48 |
Werner Enterprises Inc is a transportation and logistics company engaged in transporting truckload shipments of general commodities in both interstate and intrastate commerce. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.